Skip to Content

Coronavirus

Trial review board raises concerns about AstraZeneca vaccine data

In an unusual statement released early Tuesday, the National Institute of Allergy and Infectious Diseases said the independent board that reviews data from multiple Covid-19 vaccine candidates has raised concerns about AstraZeneca’s announcement of efficacy data from its vaccine trial. “The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which

Continue Reading

AstraZeneca vaccine is 79% effective against symptomatic Covid-19, company says

AstraZeneca’s Covid-19 vaccine showed 79% efficacy against symptomatic disease and 100% efficacy against severe disease and hospitalization in a new, US-based clinical trial, the company said Monday. The findings from the new Phase 3 trial, which included more than 32,000 participants, may boost confidence in the vaccine, which was originally developed by the University of

Continue Reading